// App-Quantinova.ai

3013 : Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

Researchers

Presenter

  • Ryan J. Sullivan

Principal Investigators

  • David S. Hong

  • Anthony W. Tolcher

  • Amita Patnaik

  • Geoffrey Shapiro

  • Bartosz Chmielowski

  • Antoni Ribas

  • Les H. Brail

  • Jennifer Roberts

  • Lucy Lee

  • Brenda O'Connell

  • Jeffrey Lorne Kutok

  • Suresh Mahabhashyam

  • Claudio Dansky Ullmann

  • Michael A. Postow

  • Jedd D. Wolchok

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • University of California, Los Angeles, Los Angeles, CA

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • Infinity Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT02637531

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved